Summary
- Current Price
- As of today, BMRN price is $60.80, up +2.48% in the most recent trading session on
- Current Price All-Time High
- BMRN price is currently -59.93% below its historical high of $151.75 set on
- Market Cap
- BMRN current market cap is $12B, up +3.72% over the past 365 days
- PE Ratio
- BMRN current PE ratio is 44.37
- Revenue
- BMRN current annual revenue is $3.24B, up +14.18% year-over-year
- Next Earnings
- The next earnings release for BMRN is on
Profile
| Metric | Value |
|---|---|
| Full Name | BioMarin Pharmaceutical Inc. |
| Ticker | NASDAQ: BMRN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | biomarin.com |
| Employees | 3,040 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $60.80 | |
| Price, 1D Change | +2.48% | |
| Market Cap | $12B | |
| - | ||
| PE Ratio | 44.37 | |
| Beta | 0.36 | |
| Revenue | $3B | |
| Revenue, 1Y Change | +14.18% | |
| EPS | $1.80 | |
| EPS, 1Y Change | -18.24% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.80 | |
| EPS Estimate | N/A | $4.93 |
| EPS Est. Change | N/A | +173.42% |
| Revenue | $3.24B | |
| Revenue Estimate | N/A | $3.87B |
| Revenue Est. Change | N/A | +19.47% |
| Current Price | $60.80 | |
| Price Target | - | $86.00 |
| Price Tgt. Change | - | +41.45% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.30 | $2.21 | -33.04% | |
| $3.26 | $1.80 | -44.59% | |
| $4.93 | N/A | +173.42% | |
| $6.39 | N/A | +254.34% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.81B | $2.84B | +0.88% | |
| $3.18B | $3.24B | +1.89% | |
| $3.87B | N/A | +19.47% | |
| $4.43B | N/A | +36.57% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +3.03% | |
| Price, 3Y | -29.76% | |
| Market Cap, 1Y | +3.72% | |
| Market Cap, 3Y | -27.84% | |
| Revenue, 1Y | +14.18% | |
| Revenue, 3Y | +58.33% | |
| EPS, 1Y | -18.24% | |
| EPS, 3Y | +140.88% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $60.80 | |
| SMA 200 | $56.09 | |
| SMA 50 | $56.22 | |
| EMA 200 | $57.09 | |
| EMA 50 | $57.24 | |
| MACD | $0.73 | |
| Beta | 0.36 | |
| ATR | $1.54 | |
| 14-Day RSI | 54.14 | |
| 10-Day Volatility | 16.50% | |
| 1-Year Volatility | 34.45% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.24B | |
| EPS | $1.80 | |
| Gross Profit | $2.48B | |
| Gross Margin | 77.27% | |
| Operating Income | $533.48M | |
| Operating Margin | 27.52% | |
| Net Income | $348.90M | |
| Net Margin | 10.76% | |
| EBITDA | $613.04M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.10 | |
| 5.21 | ||
| 3.50 | ||
| - | ||
| 5 | ||
| 5.87 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 44.37 | |
| 3.57 | ||
| 1.89 | ||
| 13.52 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $6.09B | |
| $1.56B | ||
| $7.59B | ||
| $3.95B | ||
| $1.51B | ||
| $759.03M | ||
| Total Debt | $597.18M | |
| $8.69M | ||
| $759.03M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $2.87B | ||
| $1.95B | ||
| $736.83M | ||
| $0.00 | ||
| $79.56M | ||
| $0.00 | ||
| $133.58M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $827.99M | ||
| -$414.24M | ||
| -$42.39M | ||
| Capex | $110.98M | |
| $717.02M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Citigroup | → | |
| RBC Capital | → | |
| Canaccord Genuity | → | |
| Citigroup | ||
| B of A Securities | → | |
| HC Wainwright & Co. | → | |
| Canaccord Genuity | → | |
| RBC Capital | → | |
| Morgan Stanley | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with BMRN
FAQ
What is the ticker symbol for BioMarin Pharmaceutical Inc.?
The ticker symbol for BioMarin Pharmaceutical Inc. is NASDAQ:BMRN
Does BioMarin Pharmaceutical Inc. pay dividends?
No, BioMarin Pharmaceutical Inc. does not pay dividends
What sector is BioMarin Pharmaceutical Inc. in?
BioMarin Pharmaceutical Inc. is in the Healthcare sector
What industry is BioMarin Pharmaceutical Inc. in?
BioMarin Pharmaceutical Inc. is in the Biotechnology industry
What country is BioMarin Pharmaceutical Inc. based in?
BioMarin Pharmaceutical Inc. is headquartered in United States
When did BioMarin Pharmaceutical Inc. go public?
BioMarin Pharmaceutical Inc. initial public offering (IPO) was on July 26, 1999
Is BioMarin Pharmaceutical Inc. in the S&P 500?
No, BioMarin Pharmaceutical Inc. is not included in the S&P 500 index
Is BioMarin Pharmaceutical Inc. in the NASDAQ 100?
No, BioMarin Pharmaceutical Inc. is not included in the NASDAQ 100 index
Is BioMarin Pharmaceutical Inc. in the Dow Jones?
No, BioMarin Pharmaceutical Inc. is not included in the Dow Jones index
When was BioMarin Pharmaceutical Inc. last earnings report?
BioMarin Pharmaceutical Inc.'s most recent earnings report was on May 4, 2026
When does BioMarin Pharmaceutical Inc. report earnings?
The next expected earnings date for BioMarin Pharmaceutical Inc. is August 3, 2026
Data Sources & References
- BMRN Official Website www.biomarin.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1048477/000104847726000004/0001048477-26-000004-index.htm
- BMRN Profile on Yahoo Finance finance.yahoo.com/quote/BMRN
- BMRN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/bmrn